SCCS Revision of the Opinion on Vitamin A
Vitamin A is not currently included in the Annexes of the European Cosmetics Regulation (Regulation (EC) No 1223/2009). The SCCS published the preliminary version of its revision of the scientific opinion on Vitamin A (retinol, retinyl palmitate and retinyl acetate). The deadline for comments was set at 7 February.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate

VITAMIN A AND ITS SAFETY

Vitamin A constitutes a group of lipid-soluble compounds including retinol, retinyl palmitate, retinyl acetate, retinyl linoleate and retinal. Vitamin A is a micronutrient essential for most mammalian species. According to CosIng database, retinol, retinyl palmitate and retinyl acetate are used as a skin conditioning agents in cosmetics and personal care products.

A safety dossier was submitted by Cosmetics Europe in 2012, with the aim to support the continuous use of Vitamin A in cosmetic products. It relates to the use of retinol, retinyl palmitate and retinyl acetate as cosmetic ingredients at maximum use concentrations of 0.05% RE in body lotions, 0.3% RE in hand and face creams as well as in other leave-on or rinse-off products. The Norwegian risk assessment of the use of Vitamin A (retinol and retinyl esters) was received by the European Commission in 2013.

The Commission asked the opinion of the European Medicine Agency (EMA) to exclude the possibility that, at maximum use concentrations of 0.05% RE in body lotions, 0.3% RE in hand and face creams as well as in other leave-on or rinse-off products, Vitamin A could be considered a medicinal product instead of a cosmetic product. EMA considered that “locally applied products containing Vitamin A at the maximum concentrations of 0.05% (retinol equivalents) in body lotions, 0.3% (retinol equivalents) in hand and face creams as well as in other leave-on or rinse-off products, are not considered to be medicinal products by virtue of their function“.

In 2016, the European Commission’s Scientific Committee on Consumer Safety (SCCS) issued an opinion on Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate). The teratogenic potential of Vitamin A and effects on liver and local skin effects were considered the most critical toxicological endpoints.

The SCCS concluded that Vitamin A (retinol, retinyl palmitate and retinyl acetate) at a maximum concentration of 0.05% (of retinol equivalent) in body lotions is per se safe. The SCCS also considered that Vitamin A at a maximum concentration of 0.3% in hand cream, face cream and in rinse-off products per se is safe. Baby skin care products containing Vitamin A (like body lotions and creams) were considered safe for 1-3 year old children by the SCCS.

Exposure to Vitamin A from sunscreen products, the derivatives retinyl linoleate and retinal, exposure to Vitamin A from sources other than cosmetic products, were not included or taken into in the SCCS opinion. The SCCS recognized that population’s overall exposure to Vitamin A can be significantly higher, especially because diet (followed by supplements and cosmetics) represents the most important source of Vitamin A in the population.

REVISION OF THE SCIENTIFIC OPINION ON VITAMIN A

The European Commission received additional information on a recent study, which evaluated the aggregated exposure to Vitamin A from cosmetics, diet and food supplements and the contribution of cosmetic products among the overall/total exposure to Vitamin A. The Commission requested a revision of the opinion on Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) issued in 2016 by the SCCS

The SCCS has issued a preliminary version of the requested revision. On this revision, the SCCS stated that “Vitamin A in cosmetics at the specified concentrations is safe”.

Although cosmetics alone do not exceed the upper limit allocated to Vitamin A, cosmetics containing Vitamin A may be of concern for consumers with the highest exposure (contribution from food and food supplements) because it may exceed the recommended upper limit of daily intake.

The SCCS considers that it is beyond its scope to suggest maximum concentration limits that take into account contributions from other sources (e.g., food, food supplements, etc.).

The SCCS preliminary version of the revision of the scientific opinion on Vitamin A is open for comments until 7 February 2022.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Revision of the scientific Opinion (SCCS)1576/16) on Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate). SCCS/1639/21. 2021
  3. Scientific Committee on Consumer Safety (SCCS). Opinion on Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate). SCCS/1576/16. 2016

further
reading

cosmetic products

Citral under review: SCCS Preliminary Opinion

The SCCS was tasked by the European Commission to evaluate if the safety levels for Citral, determined through QRA2 based on skin sensitization induction, are sufficient to safeguard consumers. A preliminary opinion was released.

Read More »
cosmetic products

Are sunscreens with Benzophenone-4 safe?

Benzophenone-4 is commonly known as a UV-filter in cosmetic products. Learn what the final opinion of SCCS states about Benzophenone’s safety profile as a UV-filter in cosmetic products.

Read More »
cosmetic products

Is Aluminium in cosmetics safe for human health?

The Scientific Committee on Consumer Safety (SCCS) published its Final Opinion on the safety of Aluminium in cosmetic products. This follows a lengthy review process that began in 2013 when the SCCS was first mandated to evaluate the potential health risks of Aluminium (Al) and its compounds in cosmetics.

Read More »
cosmetic products

Silver in Cosmetics: SCCS preliminary opinion.

Ingredients: SILVER

The recent preliminary opinion from the Scientific Committee on Consumer Safety (SCCS) regarding silver in cosmetics is crucial for consumers and manufacturers. This article breaks down the key points, making it easier to understand the implications and stay informed.

Read More »
news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »
cosmetic products

UK proposes ban of wet wipes containing plastic 

The UK has proposed, on April 24, 2024, a regulation titled The Environmental Protection (Wet Wipes Containing Plastic) (England) Regulations 2024, to the World Trade Organization (WTO). The regulation aims to eliminate the supply and sale of plastic-containing wet wipes, including cosmetic ones. The public can offer comments on the draft until June 23, 2024, with adoption expected in September of the same year.

Read More »
news & updates

SCCS preliminary opinion on Citral sensitization endpoint

Ingredients: CITRAL

Date of publication: 27/03/2024

On March 27 2024, the Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on the safety of Citral in cosmetic products. The deadline for comments is set to June 2, 2024.

Read More »
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »